{"filings":[{"id":95746,"accession_number":"0001104659-26-057974","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq letter on May 4, 2026, for bid price below $1.00 for 30 consecutive business days through May 1, 2026.","Must regain compliance by Nov 2, 2026, by having closing bid price ≥ $1.00 for at least 10 consecutive business days.","No immediate effect on listing; common stock continues to trade on Nasdaq under symbol HUMA.","Company intends to monitor bid price and evaluate available options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95745,"accession_number":"0001104659-26-048164","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Humacyte regains ex-U.S. rights to Symvess from Fresenius, pays low-single-digit royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Humacyte obtains sole worldwide rights to develop and commercialize Symvess; Fresenius retains U.S. distribution terms unchanged.","Humacyte will pay low-single-digit royalties on ex-U.S. net sales, with a two-year royalty-free period after launch in each country.","Existing U.S. royalties to Fresenius remain at mid-single to low double digits; Fresenius must adopt Symvess as standard of care in hemodialysis if supported.","Positions Humacyte to advance discussions with corporate partners for international and indication-specific rights.","Humacyte CEO highlights planned international expansion in Saudi Arabia and Israel for vascular injury repair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109033,"accession_number":"0001104659-26-032116","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Humacyte announces $20M registered direct offering of 25M shares at $0.80/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $20M from 25M shares at $0.80; net proceeds ~$18.4M after fees.","Offering led by a new life science dedicated investor and a long-only mutual fund.","Net proceeds to fund Symvess commercialization, hemodialysis Phase 3 read-out, and pipeline.","Expected to close March 20, 2026, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109032,"accession_number":"0001104659-26-031780","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Humacyte reports preliminary FY2025 revenue $2M, 61 Symvess units; suspends ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary FY2025: cash $50.9M, total revenue $2.0M (product $1.4M), 61 Symvess unit sales.","Received $1.48M minimum purchase commitment from KSA entity for Symvess; exclusive negotiations through July 2026.","Filed Marketing Authorization Application in Israel for Symvess in vascular trauma; also pursuing hospital-by-hospital access.","Suspended $60M ATM program effective March 19, 2026; no further sales unless new prospectus filed.","Risk factors updated; accumulated deficit $702M as of Sep 2025, company expects need for additional funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125490,"accession_number":"0001104659-25-121674","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Humacyte enters $60M at-the-market equity offering with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $60M in common stock may be sold from time to time through TD Securities (USA) LLC as agent.","TD Cowen will receive a commission of up to 3.0% of gross proceeds.","Net proceeds to fund commercialization of Symvess in vascular trauma, pipeline, and working capital.","Company is not obligated to sell any shares; ATM allows sales at prevailing market prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125489,"accession_number":"0001104659-25-121214","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Humacyte secures up to $77.5M senior secured loan facility from Avenue; draws $40M initial tranche","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan agreement provides $40M upfront, plus $12.5M delayed draw (Oct 2026-Mar 2027) and $25M discretionary tranche (Jul 2027-Jun 2028).","Term loan bears interest at greater of 11.50% or WSJ Prime + 4.50%; matures December 1, 2029.","Lenders may convert up to $2.5M of principal into common stock at 130% of warrant price.","Warrant issued to Avenue exercisable for up to ~$5M worth of common shares at initial price of $1.28, expiring December 2030.","Proceeds used for working capital, general corporate purposes, and to repay existing debt under prior revenue interest purchase agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125488,"accession_number":"0001104659-25-120915","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Humacyte terminates Revenue Interest Purchase Agreement; pays $38M cash + 5.7M shares to purchasers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Revenue Interest Purchase Agreement and Option Agreement with TPC Investments LP and Hook SA LLC as of Dec 15, 2025.","Consideration: $38 million cash (funded via new credit facility) plus 5,725,190 shares of common stock in a registered direct offering.","Offering closes Dec 15, 2025; shares issued under effective shelf registration statement (File No. 333-290231).","Company expects to fund $38M cash payment from proceeds of a new credit facility.","Satisfaction of all obligations under terminated agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125487,"accession_number":"0001104659-25-116476","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Humacyte terminates $80M at-the-market offering agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement allowed sale of up to $80M in common stock via Jefferies as agent.","Termination notice delivered November 21, 2025; effective 10 days later.","Company is not subject to any termination penalties.","No new financing or replacement agreement announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125486,"accession_number":"0001104659-25-109718","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte Q3 2025 revenue $753K from Symvess launch; net loss narrows to $17.5M; raises $56.5M post-quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $753K in Q3, all from Symvess sales; no revenue in Q3 2024.","Net loss $17.5M in Q3 vs $39.2M in Q3 2024, improved on non-cash contingent earnout remeasurement.","Cash $19.8M at Sep 30; subsequent $56.5M net proceeds from stock/warrant sale.","Symvess: 25 VAC approvals (92 hospitals eligible); 16 hospitals ordered, majority re-orders.","Pipeline: positive V007 2-year dialysis data; IND submitted for CABG; supplemental BLA planned H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":1571000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125485,"accession_number":"0001104659-25-097591","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Humacyte prices $60M registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $60.0M via sale of 28.4M shares and warrants to purchase 28.4M shares at $2.11 per unit.","Warrants exercisable at $2.11, become exercisable 180 days after issuance, expire April 7, 2031.","Offering oversubscribed with institutional investors; expected to close October 8, 2025.","D. Boral Capital acting as exclusive placement agent; fee equal to 5.75% of gross proceeds.","Offered under effective shelf registration statement (File No. 333-290231) declared effective Sept 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142228,"accession_number":"0001104659-25-090963","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Humacyte (HUMA) amends revenue interest purchase agreement; $50M repayment, discounted call option","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Company to make $50.0M repayment under Purchase Agreement from restricted cash.","Obligation to maintain $50.0M restricted cash removed; if not repaid by Dec 31, 2025, $12.5M required.","Call option at discounted repurchase price of $95.5M if exercised on or before Dec 31, 2025; up to $7.5M may be paid in stock.","Amendment executed with TPC Investments III LP and TPC Investment Solutions LP, agented by Hook SA LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142227,"accession_number":"0001818382-25-000122","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte Q2 revenue $0.3M; 82 civilian hospitals now eligible to purchase Symvess; July sales exceed H1 total","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.3M in Q2 (incl $0.1M Symvess sales); $0.8M in H1 2025 vs zero prior year.","82 civilian hospitals eligible to purchase Symvess (up from 5 in May); 13 VAC approvals covering multi-hospital networks.","ECAT approval makes Symvess available to ~35 Military Treatment Facilities and ~160 VA hospitals; first military sale in July followed by re-order.","Implemented workforce reduction of 30 employees; expects net savings ~$13.8M in 2025 and ~$38M in 2026.","Cash, cash equivalents, restricted cash $88.4M as of June 30; net cash used $6.9M in H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":818000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160234,"accession_number":"0001818382-25-000080","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Humacyte shareholders approve authorized shares increase to 350M, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares raised from 250M to 350M; vote 82.6M for, 14.1M against.","Four Class I directors elected: Dougan, Green, Seimetz, Wallace (each with >56M votes).","PwC ratified as auditor for FY2025 (95.3M for, 2.0M against, 0.6M abstain).","Annual meeting quorum 63.1% (97.9M of 155.1M shares outstanding present)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160233,"accession_number":"0001818382-25-000073","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte posts Q1 net income $39.1M; Symvess launch generates $147K revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 revenue $517K ($147K from first Symvess commercial sales); no revenue in Q1 2024.","Net income of $39.1M vs net loss of $31.9M YoY, driven by $62.3M non-cash remeasurement gain.","Cash and equivalents $113.2M; $46.7M net from March public offering extended runway.","Reduced workforce by ~31 employees; expects net savings of $13.8M in 2025, over $50M by 2026.","45 hospitals initiated Symvess VAC approval; 5 approved. On track for dialysis BLA in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":517000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160232,"accession_number":"0001818382-25-000061","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Humacyte CEO: citizen petition is baseless; signatories have conflicts of interest","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CEO Laura Niklason says petition signed by Robert E. Lee and Hooman Noorchashm is 'without merit'.","States Lee left FDA last fall and now heads Echelon, which advises Phraxis, a competitor.","Notes Noorchashm has filed nine prior FDA petitions with no resulting agency action.","Company will respond to the FDA at the appropriate time, calling claims 'false and harmful'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178533,"accession_number":"0001818382-25-000030","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte posts Q4 net loss of $20.9M; Symvess commercial launch underway after FDA approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 $20.9M vs $25.1M Q4 2023; full year net loss $148.7M vs $110.8M.","Cash $95.3M at Dec 31, 2024; raised $46.6M net in March 2025 public offering.","FDA approved Symvess Dec 19, 2024 for extremity vascular trauma; first commercial shipments to two Level 1 trauma centers in Feb 2025.","34 hospitals started VAC approval process; 3 approved; first sales recorded.","R&D expenses $88.6M in 2024 (up 16% YoY); no revenue in period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178532,"accession_number":"0001104659-25-028830","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Humacyte CEO rebuts NYT article questioning FDA approval of Symvess","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA took 19 extra weeks after PDUFA date, consulted three outside surgeons before approving Symvess on Dec 19, 2024.","Dr. Lee, cited as source, resigned from FDA months before approval; his LinkedIn says he 'retired' after a decade.","CEO disputes claim synthetic grafts never rupture; cites MAUDE database showing >25% failures from rupture/death.","In Ukrainian wartime study, all Symvess-treated limbs retained at 30 days with zero infections.","Post-approval study planned to confirm safety; prior studies on 600+ patients never halted for safety."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178531,"accession_number":"0001104659-25-028274","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Humacyte prices 25M-share public offering at $2.00/share, expects $50M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 25,000,000 shares at $2.00/share; gross proceeds ~$50M, net ~$46.6M after discounts and expenses.","Underwriters have 30-day option to purchase up to an additional 3,750,000 shares at the same price.","Proceeds to fund SYMVESS commercialization in vascular trauma, pipeline development, and working capital.","Expected to close on March 27, 2025; TD Cowen, Barclays, and BTIG are joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178530,"accession_number":"0001104659-25-027762","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Humacyte files investor presentation; no specific financial or operational details available in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation dated March 2025 made available; content not fully disclosed in this filing.","Presentation covers Humacyte's regenerative human tissue platform; no new material facts extracted.","Filing occurs under Item 8.01 as a routine update; no guidance or earnings included.","Tickers HUMA and HUMAW referenced; no price or volume data provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195207,"accession_number":"0001818382-24-000227","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Humacyte receives FDA full approval for SYMVESS in extremity arterial injury","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants full approval for SYMVESS as a vascular conduit for extremity arterial injury when autologous vein graft is not feasible.","In clinical trials, SYMVESS showed high patency rates and low rates of amputation and infection; results published in JAMA Surgery.","Sales team already recruited and trained; commercial launch preparation is underway.","SYMVESS is a first-in-class bioengineered human tissue, available off-the-shelf, eliminating the need for vein harvest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195206,"accession_number":"0001104659-24-119013","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Humacyte prices $15M registered direct offering of common stock and warrants at $5.34/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 2,808,988 shares and warrants to purchase up to 2,808,988 shares at $5.34 per unit on Nov 14, 2024.","Gross proceeds of approximately $15M before expenses; closing expected on or about Nov 15, 2024.","Warrants split: 1,404,494 expire in 180 days; 1,404,494 expire in four and one-half years, both at $5.34 exercise.","Company agrees to no further equity issuance or variable rate transactions until FDA approval for extremity vascular trauma or 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195205,"accession_number":"0001818382-24-000197","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte Q3 net loss $39.2M; ATEV BLA review ongoing with no new timeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $39.2M (Q3 2024) vs $26.0M (Q3 2023) driven by non-cash contingent earnout remeasurement.","Cash $71M at Sep 30; received $29.6M net from Oct registered direct offering.","FDA BLA for ATEV in vascular trauma still under review; no new PDUFA date provided.","V007 Phase 3 AV access data presented at ASN Kidney Week: ATEV superior patency vs fistula in key subgroups.","Submitted NTAP reimbursement application to CMS for FY2026 cycle (Oct 2025 effective date if approved)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195204,"accession_number":"0001818382-24-000192","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Humacyte ATEV meets Phase 3 co-primary endpoints; superior to AV fistula in hemodialysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATEV showed functional patency 81.3% at 6 months vs 66.4% for AV fistula; secondary patency 68.3% vs 62.2% at 12 months (joint p=0.0071).","Subgroup analyses: ATEV superior in female (p<0.0001), obese (p=0.0001), and diabetic (p=0.0024) patients for patency rates and hemodialysis duration.","Thrombosis reported in 52.1% of ATEV patients vs 9.1% for AV fistula; 94% of thrombotic events successfully treated.","Infection rates low and similar: 9.1% ATEV vs 9.9% AV fistula.","Phase 3 trial enrolled 242 hemodialysis patients in US; ATEV is investigational and not yet FDA-approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195203,"accession_number":"0001104659-24-106404","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Humacyte prices $30M registered direct offering of common stock and warrants at $5.28/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5,681,820 common shares and 5,681,820 warrants at $5.28 per unit.","Gross proceeds approximately $30M before fees and expenses.","Warrants split: 2,840,910 expire in 6 months; 2,840,910 expire in 4.5 years; exercise price $5.28 each.","Expected to close October 7, 2024; EF Hutton acting as placement agent with 6% fee plus expense cap.","Offered under effective shelf registration statement on Form S-3 (File No. 333-267225)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211466,"accession_number":"0001104659-24-102498","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Humacyte enters $50M equity purchase agreement with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company can sell up to $50M of common stock to Lincoln Park over 24 months at its discretion.","Purchase price is 97% of the lower of the daily low or average of three lowest closing prices over prior 10 days.","Shares not sold below $1.00 floor price; maximum regular purchase of 100,000 shares or $1.5M per day.","Commitment fee of 115,705 shares issued to Lincoln Park; net proceeds for R&D, commercial launch, and working capital.","Lincoln Park agrees not to engage in short-selling or hedging during the term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211465,"accession_number":"0001818382-24-000153","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"FDA delays ATEV trauma BLA review beyond PDUFA date; Q2 net loss $56.7M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA notified Humacyte on Aug 9 that additional time needed to complete ATEV BLA review; PDUFA date was Aug 10; no revised action date yet.","Q2 net loss $56.7M vs $22.7M YoY, driven by $27.2M non-cash earnout remeasurement and higher R&D costs.","ATEV V007 Phase 3 trial in hemodialysis showed superior functional patency vs autogenous fistula at 6 and 12 months (p=0.0071).","Cash $93.6M at June 30, 2024; H1 net cash provided $13.1M from $43M public offering and $20M Oberland draw.","R&D expense $23.8M (+16% YoY); G&A $5.7M (-8% YoY); no revenue reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211464,"accession_number":"0001818382-24-000146","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Humacyte ATEV meets Phase 3 endpoints in hemodialysis access; superiority over standard of care","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATEV showed superior functional patency at 6 months (81.3% vs 66.4%) and secondary patency at 12 months (68.3% vs 62.2%); p=0.0071.","ATEV also demonstrated significantly longer hemodialysis duration over 12 months (p=0.0162).","Company plans to discuss potential market authorization pathway with FDA soon.","More adverse events were reported in the ATEV arm compared to the fistula arm.","Over 800,000 Americans have end-stage renal disease; ATEV is an off-the-shelf bioengineered vessel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230111,"accession_number":"0001818382-24-000102","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Humacyte holds 2024 annual meeting; re-elects six directors and ratifies PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["John P. Bamforth, Emery N. Brown, Michael T. Constantino, Keith Anthony Jones, Laura E. Niklason, Susan Windham-Bannister elected as Class III directors.","Bamforth and Jones resigned and were immediately reappointed as Class II directors to rebalance board to four directors per class.","Ratification of PricewaterhouseCoopers LLP as independent auditor for FY2024: 69,075,479 for, 883,816 against, 72,146 abstain.","Quorum achieved with 70,031,441 shares (58.8% of outstanding) present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230110,"accession_number":"0001818382-24-000054","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte Q1 net loss $31.9M; FDA grants Priority Review for HAV, PDUFA Aug 10, 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $31.9M vs $37.0M YoY; no revenue; cash $115.5M, up from $35.1M net provided.","BLA for HAV in vascular trauma accepted with Priority Review; PDUFA date Aug 10, 2024.","Raised ~$43M net from public offering in March 2024; additional $20M draw from Oberland facility.","Total operating expenses $26.6M flat QoQ; R&D $21.3M up from $17.3M YoY.","Preparations for US launch ongoing: hired VP Sales, completed Budget Impact Model, seeking ICD-10 code."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}